Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.31 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 2/20 | 0.31 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
| ▸ | CPA3 | P15088 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107537 | 0.86 | GRIA1 (0.35) | GRIA1GRIK1GRIA2GRIA3GRIA4 | |
| SCHEMBL6537411 | 0.80 | KMO (0.36) | GRIA1GRIK1GRIA2GRIA3GRIA4 | |
| SCHEMBL5282402 | 0.79 | GRIA1 (0.51) | GRIA1GRIK1GRIA2GRIA3GRIA4 | |
| SCHEMBL26779812 | 0.77 | CDK4 (0.39) | — | |
| SCHEMBL26779833 | 0.77 | CDK4 (0.39) | — | |
| SCHEMBL6037197 | 0.71 | KDM3B (0.35) | GRIA1GRIK1GRIA2GRIA3GRIA4 | |
| SCHEMBL667079 | 0.71 | ALDH1A1 (0.33) | GRIA1GRIK1 | |
| SCHEMBL4348692 | 0.70 | ADRA1D (0.37) | CYP1A2 | |
| SCHEMBL26779814 | 0.70 | TSHR (0.40) | GRIA1GRIA2GRIA3GRIA4B3GNT2 | |
| SCHEMBL4347789 | 0.70 | TYMP (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1576116-A4 | METHODS AND MATERIALS RELATING TO NOVEL POLYPEPTIDES AND POLYNUCLEOTIDES | NUVELO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1809321-A2 | ADOPTIVE IMMUNOTHERAPY WITH ENHANCED T LYMPHOCYTE SURVIVAL | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007037780-A2 | ADOPTIVE IMMUNOTHERAPY WITH ENHANCED T LYMPHOCYTE SURVIVAL | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-04-05 | — | — | WO | disclosed |
| EP-1576116-A2 | METHODS AND MATERIALS RELATING TO NOVEL POLYPEPTIDES AND POLYNUCLEOTIDES | Nuvelo, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004007672-A2 | METHODS AND MATERIALS RELATING TO NOVEL POLYPEPTIDES AND POLYNUCLEOTIDES | NUVELO, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2002081686-A2 | NUCLEIC ACIDS BINDING A NEUROPEPTIDE | NASCACELL GMBH (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002081510-A2 | PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME | CURAGEN CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020035056-A1 | 54420, a novel human calcium channel | MILLENNIUM PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |